GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » Price-to-Owner-Earnings

Eledon Pharmaceuticals (FRA:2TK) Price-to-Owner-Earnings : (As of Jun. 19, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals Price-to-Owner-Earnings?

As of today (2024-06-19), Eledon Pharmaceuticals's share price is €2.56. Eledon Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Eledon Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:


FRA:2TK's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.725
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-19), Eledon Pharmaceuticals's share price is €2.56. Eledon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.28. Therefore, Eledon Pharmaceuticals's PE Ratio for today is At Loss.

As of today (2024-06-19), Eledon Pharmaceuticals's share price is €2.56. Eledon Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was €-1.28. Therefore, Eledon Pharmaceuticals's PE Ratio without NRI for today is At Loss.


Eledon Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Eledon Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eledon Pharmaceuticals Price-to-Owner-Earnings Chart

Eledon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Eledon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Eledon Pharmaceuticals's Price-to-Owner-Earnings

For the Biotechnology subindustry, Eledon Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eledon Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Eledon Pharmaceuticals's Price-to-Owner-Earnings falls into.



Eledon Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Eledon Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.56/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eledon Pharmaceuticals  (FRA:2TK) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Eledon Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Eledon Pharmaceuticals (FRA:2TK) Business Description

Traded in Other Exchanges
Address
19900 MacArthur Boulevard, Suite 550, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.

Eledon Pharmaceuticals (FRA:2TK) Headlines

No Headlines